Home›Stock Screener›Vaishali Pharma›Intrinsic Value

Vaishali Pharma Intrinsic Value

Vaishali Pharma intrinsic value. Vaishali Pharma (VAISHALI) median intrinsic value is ₹13.26 from 9 valuation models (range ₹4–₹20), vs current price ₹6.63 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Analyse Vaishali Pharma ownership pattern to track promoter, FII and institutional holdings.

Market Price (CMP)
₹6.63
Primary Intrinsic Value
₹14.08
Market Cap
₹17.2 Cr
+100.0% Upside
Median Value
₹13.26
Value Range
₹4 - ₹20
Assessment
Trading Below Calculated Value
Safety Margin
50.0%

VAISHALI Valuation Methods Summary — DCF, Graham Number & P/E

Vaishali Pharma intrinsic value across 9 models vs current price ₹6.63 — upside/downside and value range per method. Browse Vaishali Pharma annual reports for revenue, profit, balance sheet and cash flow data.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹14.08 ₹11.26 - ₹16.90 +112.4% EPS: ₹0.64, Sector P/E: 22x
Book Value Method asset ₹16.57 ₹14.91 - ₹18.23 +149.9% Book Value/Share: ₹26.54, P/B: 2.0x
Revenue Multiple Method revenue ₹13.26 ₹11.93 - ₹14.59 +100.0% Revenue/Share: ₹47.69, P/S: 2.0x
EBITDA Multiple Method earnings ₹13.26 ₹11.93 - ₹14.59 +100.0% EBITDA: ₹12.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹3.57 ₹2.86 - ₹4.28 -46.2% CF Growth: 5.0%, Discount: 15%
PEG Ratio Method growth ₹4.10 ₹3.69 - ₹4.51 -38.2% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹9.89 ₹8.90 - ₹10.88 +49.2% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹13.26 ₹11.93 - ₹14.59 +100.0% ROE: 11.6%, P/E Multiple: 12x
Graham Defensive Method conservative ₹19.55 ₹17.60 - ₹21.51 +194.9% EPS: ₹0.64, BVPS: ₹26.54
Method Types: Earnings Asset DCF Growth Dividend Conservative

VAISHALI Intrinsic Value vs Market Price — All Valuation Models

Vaishali Pharma fair value range ₹4–₹20 vs current market price ₹6.63 across 9 valuation models. For current market price and key ratios, visit VAISHALI stock price BSE.

VAISHALI Intrinsic Value Analysis — Undervalued or Overvalued?

Vaishali Pharma median intrinsic value ₹13.26, current price ₹6.63 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.

What is the intrinsic value of VAISHALI?

Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Vaishali Pharma (VAISHALI) is ₹13.26 (median value). With the current market price of ₹6.63, this represents a +100.0% variance from our estimated fair value.

The valuation range spans from ₹3.57 to ₹19.55, indicating ₹3.57 - ₹19.55.

Is VAISHALI undervalued or overvalued?

Based on our multi-method analysis, Vaishali Pharma (VAISHALI) appears to be trading below calculated value by approximately 100.0%.

VAISHALI Financial Health — Key Ratios vs Industry Benchmarks

Vaishali Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 11.6% Industry Standard: 15%+ Above 10% Measures shareholder return efficiency
Operating Margin 7.0% Industry Standard: 20%+ Below 10% Indicates operational efficiency level
Asset Turnover Ratio 1.01x Industry Standard: 1.0x+ Above 1.0x Measures asset utilization efficiency

VAISHALI Cash Flow Quality — Operating & Free Cash Flow

Vaishali Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹0 Cr ₹-3 Cr Negative Cash Flow 3/10
March 2025 ₹-18 Cr ₹-18 Cr Negative Cash Flow 3/10
March 2024 ₹1 Cr ₹1 Cr Positive Free Cash Flow 8/10
March 2023 ₹1 Cr ₹1 Cr Positive Free Cash Flow 8/10
March 2022 ₹1 Cr ₹1 Cr Positive Free Cash Flow 7/10